Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 4/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27392612 | 0.79 | — | — | |
| SCHEMBL24954520 | 0.76 | LMNA (0.41) | ALDH1A1PARP1 | |
| SCHEMBL1016019 | 0.76 | PNMT (0.49) | METAP1 | |
| SCHEMBL1016046 | 0.76 | PNMT (0.41) | METAP1AADATHTR2AHTR2CHTR2B | |
| SCHEMBL1015335 | 0.76 | PNMT (0.49) | METAP1 | |
| SCHEMBL1016672 | 0.76 | ACHE (0.41) | ACHEPARP10PARP1HTR2AHTR2B | |
| SCHEMBL14380007 | 0.76 | DRD3 (0.46) | ACHE | |
| SCHEMBL1015336 | 0.76 | PNMT (0.49) | METAP1 | |
| SCHEMBL10225793 | 0.76 | DRD2 (0.50) | ACHEMETAP1 | |
| SCHEMBL10609048 | 0.76 | ACHE (0.39) | ACHEMETAP1AADATALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988592-B2 | Organic compounds | Givaudan, S.A. (CH) | 2018-06-05 | — | — | US | claimed |
| US-20170218299-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2017-08-03 | — | — | US | claimed |
| US-20160075627-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-03-17 | — | — | US | claimed |
| EP-2994448-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-03-16 | — | — | EP | claimed |
| CN-105189432-A | Improvements in or relating to organic compounds | GIVAUDAN SA | 2015-12-23 | — | — | CN | claimed |
| WO-2014180952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-11-13 | — | — | WO | claimed |
| CN-113873884-B | Arthropod control composition | 弗门尼舍有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-10457891-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2019-10-29 | — | — | US | disclosed |
| US-20180251706-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-09-06 | — | — | US | disclosed |
| US-9988592-B2 | Organic compounds | Givaudan, S.A. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170218299-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2017-08-03 | — | — | US | disclosed |
| US-9656938-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20160075627-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-03-17 | — | — | US | disclosed |
| EP-2994448-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-03-16 | — | — | EP | disclosed |
| CN-105189432-A | Improvements in or relating to organic compounds | GIVAUDAN SA | 2015-12-23 | — | — | CN | disclosed |
| WO-2014180952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075627-A1 | ORGANIC COMPOUNDS | AOX1, TYR, ALK | ACHE 1114/4885METAP1 1705/4885AADAT 1089/4885 |
| US-20180251706-A1 | ORGANIC COMPOUNDS | AOX1, TYR, ALK | ACHE 1114/4885METAP1 1705/4885AADAT 1089/4885 |
| US-20170218299-A1 | ORGANIC COMPOUNDS | AOX1, TYR, ALK | ACHE 1114/4885METAP1 1705/4885AADAT 1089/4885 |
| US-10457891-B2 | Organic compounds | AOX1, TYR, ALK | ACHE 1114/4885METAP1 1705/4885AADAT 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.